(Q38389312)

2 September 2017

1 reference

title

Lentiviral vectors in cancer immunotherapy (English)

1 reference

2 September 2017

1 reference

Robyn Aa Oldham

1

1 reference

2 September 2017

Elliot M Berinstein

series ordinal

2

1 reference

2 September 2017

Jeffrey A Medin

series ordinal

3

1 reference

2 September 2017

publication date

1 January 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

7

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

271-284

1 reference

Cancer regression in patients after transfer of genetically engineered lymphocytes

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Adenoviruses as gene-delivery vehicles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Quantitative analysis of the packaging capacity of recombinant adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

HIV-1 accessory proteins--ensuring viral survival in a hostile environment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Progress with retroviral gene vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Encapsidation sequences for spleen necrosis virus, an avian retrovirus, are between the 5' long terminal repeat and the start of the gag gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Transcriptional activation by tetracyclines in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Hot spots of retroviral integration in human CD34+ hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat β-thalassemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Hepatic lentiviral gene transfer is associated with clonal selection, but not with tumor formation in serially transplanted rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Effective gene therapy with nonintegrating lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Targeted genome modifications using integrase-deficient lentiviral vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

A library of TAL effector nucleases spanning the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

DNA targeting specificity of RNA-guided Cas9 nucleases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Multiplex genome engineering using CRISPR/Cas systems

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Precision genome engineering with programmable DNA-nicking enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Sipuleucel-T and immunotherapy in the treatment of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

T-cell tolerance or function is determined by combinatorial costimulatory signals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

CD8 T Cell Clonal Expansion and Development of Effector Function Require Prolonged Exposure to Antigen, Costimulation, and Signal 3 Cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Targeting dendritic cell signaling to regulate the response to immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Proliferating dendritic cell progenitors in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Enhanced immunogenicity of B cell lymphoma genetically engineered to express both B7-1 and interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Localized interleukin-12 delivery for immunotherapy of solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Transfer of specificity by murine alpha and beta T-cell receptor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Treatment of advanced leukemia in mice with mRNA engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

Successful Immunization with a Single Injection of Non-integrating Lentiviral Vector

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.108

21 January 2018

Identifiers

DOI

10.2217/IMT.14.108

1 reference

2 September 2017

1 reference